It is currently Sat Feb 28, 2015 11:28 am
GNbAC1 has successfully completed Phase I in healthy volunteers showing that GNbAC1 is very well tolerated. GNbAC1 has also successfully completed Phase IIa last year, demonstrating an optimal safety profile and encouraging signs of efficacy on a first mall cohort of MS patients.
Information about the clinical trials are posted on http://www.clinicaltrials.gov,
identifiers NCT01639300 & NCT01699555.
The present study reported a significant CCT (cerebral circulation time) increase in MS patients compared to control subjects, indicating a consistent condition of cerebral hypoperfusion. Increase of CCT, and the ...
Total posts 223874 • Total topics 23316 • Total members 14752